References
- Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail [Internet]. 2013 May 24 [cited 2015 Apr 1];6(3):606–619. Available from: http://circheartfailure.ahajournals.org/content/early/2013/04/24/HHF.0b013e318291329a
- Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea. results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. Elsevier Inc.; 2010;55(19):2062–2076.
- Lee S-C, Stevens TL, Sandberg SM, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail [Internet]. 2002 Jun [cited 2015 Jun 22];8(3):149–154. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12140807
- Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet (London, England) [Internet]. 1997 Nov 8 [cited 2015 Jun 22];350(9088):1349–1353. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9365448
- Stevenson LW. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA J Am Med Assoc [Internet]. American Medical Association; 1989 Feb 10 [cited 2015 Jun 22];261(6):884. Available from: http://jama.jamanetwork.com/article.aspx?articleid=376284
- Androne AS, Hryniewicz K, Hudaihed A, et al. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol [Internet]. 2004 May 15 [cited 2015 Jul 26];93(10):1254–1259. Available from: http://www.sciencedirect.com/science/article/pii/S0002914904002255
- Müller MM, Hackl W, Griesmacher A. [Point-of-care-testing–the intensive care laboratory]. Anaesthesist [Internet]. 1999 Jan [cited 2016 Jan 21];48(1):3–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10073241
- Stürenburg E, Junker R. Point-of-care testing in microbiology: the advantages and disadvantages of immunochromatographic test strips. Dtsch ÄRzteblatt Int [Internet]. 2009 Jan [cited 2016 Jan 21];106(4);48–54. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2695304&tool=pmcentrez&rendertype=abstract
- Francis AJ, Martin CL. A practical example of PoCT working in the community. Clin Biochem Rev [Internet]. 2010 Aug [cited 2015 Nov 12];31(3);93–97. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2924129&tool=pmcentrez&rendertype=abstract
- Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol [Internet]. Elsevier; 2005 Apr 15 [cited 2015 Jun 4];95(8):948–954. Available from: http://www.ajconline.org/article/S0002914905001153/fulltext
- Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart [Internet]. 2006 Jun [cited 2015 Jun 22];92(6);843–849. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1860679&tool=pmcentrez&rendertype=abstract
- Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation [Internet]. 2004 Oct 12 [cited 2015 Apr 19];110(15):2168–2174. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15451800
- Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J [Internet]. Elsevier; 1998 May 5 [cited 2015 Jul 26];135(5):914–923. Available from: http://www.ahjonline.com/article/S0002870398700547/fulltext
- Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol [Internet]. 2001 Feb [cited 2015 Jun 22];37(2):379–385. Available from: http://www.sciencedirect.com/science/article/pii/S0735109700011566
- Wang AY-M, Lai K-N. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol [Internet]. 2008 Sep 1 [cited 2015 Jun 22];19(9):1643–1652. Available from: http://jasn.asnjournals.org/content/19/9/1643.full
- Yandle TG, Richards AM, Nicholls MG, et al. Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci [Internet]. 1986 May [cited 2015 Jul 26];38(20);1827–1833. Available from: http://www.sciencedirect.com/science/article/pii/0024320586901372
- Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail [Internet]. 2001 Mar [cited 2015 Jun 22];7(1):21–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11264546
- Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med [Internet]. 2002;347(3): 161–167. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12124404
- Lainscak M, Von Haehling S, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers. Int J Cardiol [Internet]. 2009 Mar 6 [cited 2015 Jul 26];132(3):303–311. Available from: http://www.sciencedirect.com/science/article/pii/S0167527308013120
- Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357–2368.
- Hobbs RE, Mills RM. Endogenous B-type natriuretic peptide: a limb of the regulatory response to acutely decompensated heart failure. Clin Cardiol [Internet]. 2008 Sep [cited 2016 Jan 17];31(9);407–412. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18781599
- Silver MA, Maisel A, Yancy CW, et al. BNP consensus panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail [Internet]. 2004 [cited 2015 Jul 26];10(5 Suppl 3):1–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15604859
- Bayés-Genís A, Barallat J, Galán A, et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol [Internet]. 2015 Feb 24 [cited 2016 Jan 17];65(7):657–665. Available from: http://content.onlinejacc.org/article.aspx?articleid=2119404
- McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med [Internet]. 2014 Aug 30 [cited 2014 Aug 30];371(11):140830040023009. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25176015
- Jaffe AS. Unwinding the interaction of natriuretic peptides and neprilysin. J Am Coll Cardiol [Internet]. 2015 Feb 24 [cited 2015 Dec 13];65(7):666–667. Available from: http://content.onlinejacc.org/article.aspx?articleID=2119409
- Luckenbill KN, Christenson RH, Jaffe AS, et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC committee for standardization of markers of cardiac damage. Clin Chem [Internet]. 2008 Mar 1 [cited 2016 Jan 17];54(3):619–621. Available from: http://www.clinchem.org/content/54/3/619.long
- Maisel A, Mueller C, Adams K, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail [Internet]. 2008 Sep [cited 2015 Jun 2];10(9):824–839. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18760965
- Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med [Internet]. 2004 Mar 12 [cited 2015 Jun 29];350(7):647–654. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14960741
- McDonagh TA, Holmer S, Raymond I, et al. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail [Internet]. 2004 Mar 20 [cited 2015 Jun 29];6(3):269–273. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14987575
- Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of NT-proBNP study. Eur Heart J [Internet]. 2006 Mar [cited 2015 Jun 29];27(3):330–337. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16293638
- Clerico A, Iervasi G, Del Chicca MG, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest [Internet]. 1998 Mar [cited 2015 Jun 24];21(3):170–179. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9591213
- Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol [Internet]. 2001 Dec [cited 2015 Jun 28];38(7);1934–1941. Available from: http://www.sciencedirect.com/science/article/pii/S0735109701016722
- Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol [Internet]. 2004 Feb 18 [cited 2015 Jun 22];43(4):635–641. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14975475
- Valle R, Aspromonte N, Milani L, et al. Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels. Heart Fail Rev [Internet]. 2011 Nov [cited 2015 May 18];16(6):519–529. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3151484&tool=pmcentrez&rendertype=abstract
- Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet (London, England) [Internet]. 2000 Apr 1 [cited 2015 Jul 2];355(9210):1126–1130. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10791374
- Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death) trial. J Am Coll Cardiol [Internet]. 2009 Dec 29 [cited 2015 Apr 19];55(1):53–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20117364
- Sanders-van Wijk S, Maeder MT, Nietlispach F, et al. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF. Circ Heart Fail [Internet]. 2014 Jan 18 [cited 2015 Jun 1];7(1):131–139. Available from: http://circheartfailure.ahajournals.org/content/early/2013/12/18/CIRCHEARTFAILURE.113.000527
- Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. JAMA [Internet]. 2009 Jan 28 [cited 2015 Jul 2];301(4):383–392. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19176440
- Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation [Internet]. 2004 Feb 10 [cited 2015 May 27];109(5):594–600. Available from: http://circ.ahajournals.org/content/109/5/594.full.
- Krauser DG, Lloyd-Jones DM, Chae CU, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP investigation of dyspnea in the emergency department (PRIDE) substudy. Am Heart J [Internet]. 2005 Apr [cited 2015 Jul 2];149(4):744–750. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15990762
- Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol [Internet]. 2006 Jan 3 [cited 2015 Jul 2];47(1):85–90. Available from: http://content.onlinejacc.org/article.aspx?articleid=1137150
- Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RRJ, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med [Internet]. American Medical Association; 2007 Feb 26 [cited 2015 Jul 2];167(4):400–407. Available from http://archinte.jamanetwork.com/article.aspx?articleid=411764
- Tsutamoto T, Wada A, Sakai H, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol [Internet]. 2006 Feb 7 [cited 2015 May 17];47(3):582–586. Available from: http://content.onlinejacc.org/article.aspx?articleid=1137251
- Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP investigation of dyspnea in the emergency department (PRIDE) study. J Am Coll Cardiol [Internet]. 2006 Jan 3 [cited 2015 Jul 2];47(1):91–97. Available from: http://www.sciencedirect.com/science/article/pii/S0735109705023521
- de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med [Internet]. 2001 Oct 4 [cited 2015 Jun 22];345(14):1014–1021. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11586953
- Hussein AA, Saliba WI, Martin DO, et al. Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation [Internet]. 2011 May 17 [cited 2015 Jun 22];123(19):2077–2082. Available from: http://circ.ahajournals.org/content/123/19/2077.full
- Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation [Internet]. 2003 Nov 4 [cited 2015 Jun 22];108(18):2191–2194. Available from: http://circ.ahajournals.org/content/108/18/2191.full
- Pruszczyk P, Kostrubiec M, Bochowicz A, et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J [Internet]. 2003 Oct 1 [cited 2015 Jun 22];22(4):649–653. Available from: http://erj.ersjournals.com/content/22/4/649.long
- Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol [Internet]. 1998 Jan [cited 2015 Jul 6];31(1):202–208. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9426041
- Casals G, Ros J, Sionis A, et al. Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am J Physiol Heart Circ Physiol [Internet]. 2009 Aug 1 [cited 2015 Jun 22];297(2):H550–H555. Available from: http://ajpheart.physiology.org/content/297/2/H550.full
- Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med [Internet]. 2008 Oct 2 [cited 2015 Nov 12];359(14):1464–1476. Available from: http://europepmc.org/abstract/med/18779236
- Macnab AJ, Grant G, Stevens K, et al. Cost: benefit of point-of-care blood gas analysis vs. laboratory measurement during stabilization prior to transport. Prehosp Disaster Med [Internet]. 2003 [cited 2015 Nov 12];18(1):24–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14694897
- Soremekun OA, Datner EM, Banh S, et al. Utility of point-of-care testing in ED triage. Am J Emerg Med [Internet]. 2013 Feb [cited 2015 Nov 12];31(2);291–296. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23083886
- Christenson ES, Collinson PO, Defilippi CR, et al. Heart failure biomarkers at point-of-care: current utilization and future potential. Expert Rev Mol Diagn [Internet]. 2014 Mar [cited 2016 Jan 21];14(2);185–197. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24524847
- Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J [Internet]. 2001 Mar [cited 2015 Jun 24];141(3):367–374. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11231433
- Maisel A, Barnard D, Jaski B, et al. Primary results of the HABIT trial (heart failure assessment with BNP in the home). J Am Coll Cardiol [Internet]. 2013 Apr 23 [cited 2016 Jan 1];61(16):1726–1735. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23500322
- Maisel AS, Shah KS, Barnard D, et al. How B-type natriuretic peptide (BNP) and body weight changes vary in heart failure with preserved ejection fraction compared with reduced ejection fraction: secondary results of the HABIT (HF assessment with BNP in the home) trial. J Card Fail [Internet]. 2015 Oct 31 [cited 2015 Nov 6]. Available from http://www.ncbi.nlm.nih.gov/pubmed/26433086
- Zugck C, Nelles M, Katus HA, et al. Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood. Clin Chem Lab Med [Internet]. 2006 Jan [cited 2015 Nov 12];44(10):1269–1277. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17032141
- Ro R, Thode HC, Taylor M, et al. Comparison of the diagnostic characteristics of two B-type natriuretic peptide point-of-care devices. J Emerg Med [Internet]. 2011 Dec [cited 2015 Sep 28];41(6);661–667. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21620610
- Kosowsky JM, Weiner C, Aronson AA, et al. Impact of point-of-care B-type natriuretic peptide (BNP) measurement on medical decision-making for older emergency department patients with dyspnea. J Emerg Med [Internet]. 2006 Aug [cited 2015 Nov 12];31(2);147–150. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17044575
- Nichols JH, Poe SS. Quality assurance, practical management, and outcomes of point-of-care testing: laboratory perspectives, part I. Clin Lab Manage Rev [Internet]. 1999 [cited 2015 Nov 12];13(6):341–350. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10747660
- Shah K, Terracciano GJ, Jiang K, et al. Comparability of results between point-of-care and automated instruments to measure B-type natriuretic peptide. West J Emerg Med [Internet]. 2010 Feb [cited 2015 Nov 12];11(1);44–48. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2850853&tool=pmcentrez&rendertype=abstract
- Prontera C, Masotti S, Franzini M, et al. Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform. Clin Chem Lab Med [Internet]. 2015 Apr [cited 2016 Jan 21];53(5):e125–e127. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25372724
- Clerico A, Passino C, Franzini M, et al. Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. Clin Chim Acta [Internet]. 2015 Mar 30 [cited 2015 Dec 13];443:17–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24937843
- Prontera C, Zaninotto M, Giovannini S, et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study. Clin Chem Lab Med [Internet]. 2009 Jan [cited 2016 Jan 25];47(6):762–768. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19402791
- Nosanchuk JS, Keefner R. Cost analysis of point-of-care laboratory testing in a community hospital. Am J Clin Pathol [Internet]. 1995 103(2);240–243. Feb [cited 2015 Nov 12]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/7856570
- Kost GJ. The Laboratory-Clinical Interface *. CHEST J [Internet]. American College of Chest Physicians; 1999 Apr 1 [cited 2015 Nov 12];115(4):1140–1154. Available from: http://journal.publications.chestnet.org/article.aspx?articleid=1077113#PotentialAdvantagesandDisadvantages